% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • biobottom biobottom Jan 14, 2011 5:09 PM Flag

    OT: Ariad's Ridaforolimus...

    Ariad is my other favorite biotech, besides IMGN. Thinking IMGN won't do much for a while, as suggested by another poster. Would like to get into a new one, and spread out my bets, get blood moving. Any thoughts on Curis? I rode Vical up and down, and that got old. Thanks for any new ideas.
    GLTA BioBottom

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You might check out SGEN
      A bunch of wizards
      developing "markers" including a new MS approach..

      For a remarkable BIOTECH (trio) arbitrage
      starring CLSP.OB - SGYO.OB and IRWD , a potential opportunity to see a $0.64 stock (CLSP) turn into a $ 7.- treasure.

      Check this out:
      The Best Biotech Arbitrage Opportunity
      (Seeking Alpha November 12 2010)


    • OT, you asked about Curis and it is my largest holding followed closely by IMGN. There was an article this week that drove the stock up over 50% but it still has a way to go IMO. Both IMGN and Curis are similar in the fact they both have agreements with Gennetech and both have so far shown great results in testing and they both have cash to last about 2 more years, although at this point I think the cash balance for IMGN will last them a little longer. I do believe Curis will have an offering shortly which will drop the price temporarily but then investors will want to get in before the phase 2 results come in which will drive it back up again. My personal hope is they raise another $20 million or so to give them more breathing room since nothing with the FDA is assured as IMGN investors know. The current price for Curis is almost like buying a call that doesn't expire.

      They, like IMGN, are going to submit for accelerated approval based on a phase 2 trial (Curis' trial is a pivotal phase 2 trial) and hopefully have different results than IMGN did last summer. The big difference in the phase 2 trials is Curis, actually Genentech, designed their phase 2 with the FDA prior to the start since the phase 1 showed such amazing results. There are currently 29 clinical trials underway for the compound developed jointly by Curis and Gennetech and it hasn't even been approved.

      You know the story, if it gets approved, the stock explodes and if there is a delay, it implodes. The recent article gave price targets of between $.50 and $40 or more with approval, pretty wide range don't you think LOL? The drug works it is all a matter of timing. If you are interested I have provided a bunch of links over at the CRIS board to begin your dd.

      This year IMO Curis will have much more volatility than IMGN and I believe also has more risk based on it's current cash position. With that risk, I also think the potential reward is much greater though. The company is much smaller than IMGN and only has about 35 employees so it won't take much revenue to make it extremely profitable.

      Good luck and hopefully both IMGN and CRIS take off in the near term.

    • Biobottom - Since you asked, my tech portfolio is DNDN, IMGN, ARIA, AVII, and diagnostic, CPHD. AVII might be the best of the lot at this point for high risk/high reward. CPHD is maturing, but still has a lot of upside IMO.

      Another high risk/high reward to get your blood going is microturbine company, CPST. I love their product.

      Good Luck and do your own full Due Diligence.

2.77-0.05(-1.77%)Sep 26 4:00 PMEDT